Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL) Meeting Abstract
| Authors: | Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; Farooq, U.; van Meerten, T.; Ulrickson, M.; Elsawy, M.; Leslie, L.; Chaganti, S.; Dickinson, M.; Yang, Y.; Schupp, M.; To, C.; Locke, F. |
| Abstract Title: | Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 271 |
| End Page: | 272 |
| Language: | English |
| ACCESSION: | WOS:001091456900607 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: P767 -- Source: Wos |
